Fighting the Loneliness

I haven’t always had to fight loneliness and isolation. When I was younger I loved going out to listen to live music. Dancing was a fun way for me to interact with others. I enjoyed being social and was always looking for a place to meet friends at a bar or show. All of that has changed since my diagnosis of schizoaffective disorder.  Fighting loneliness has become part of my new normal. Isolating myself because of my mental illness can easily lead to loneliness and depression in my life now. One Saturday evening a few years ago I decided to count how many beers I had consumed in a 24 hour period. I counted 19. I realized at that moment I couldn’t just have one beer, but I had to have a lot of beer, or nothing at all.  Before my diagnosis of schizoaffective disorder, my lifestyle involved going out to bars to drink with my friends. At the time that was my social outlet. However, after my diagnosis I quit drinking alcohol. I was used to spending a lot of money on alcohol. That was another reason I stopped drinking… it was too expensive.  Another reason I stopped abusing alcohol was for health reasons. An unhealthy lifestyle led to a size 42 inch waistline, but I also knew that the excessive drinking was doing damage to other parts of my body, as well.  The first couple of weeks of not drinking on a Friday night were especially tough for me.  I missed even the minor chit chat that occurred in those settings because alcohol provided li...
Source: Psych Central - Category: Psychiatry Authors: Tags: Antidepressants Antipsychotics Atypical Antipsychotics Personal Stories Schizoaffective Disorder Schizophrenia Combat Veteran Loneliness Mood Disorder Music Therapy Psychosis Seasonal Affective Disorder Social Isolation Suicidal Source Type: news

Related Links:

Publication date: Available online 3 July 2020Source: Journal of Food EngineeringAuthor(s): Llanquileo Luis, Gamboa Alexander, Abugoch Lilian, Tapia Cristian
Source: Journal of Food Engineering - Category: Food Science Source Type: research
Publication date: Available online 3 July 2020Source: Spatial and Spatio-temporal EpidemiologyAuthor(s): Felix Tran, Christopher Morrison
Source: Spatial and Spatio-temporal Epidemiology - Category: Epidemiology Source Type: research
Abstract Major depressive disorder is a prevalent and serious form of mental illness. While traditional antidepressants ameliorate some of the symptoms associated with depression, the onset of action typically takes several weeks leaving severely depressed individuals vulnerable to self-injurious behavior and possibly suicide. There has been a major unmet need for the development of pharmacological therapies that can quickly alleviate symptoms associated with depression. Clinical data shows that a single sub-psychomimetic dose of ketamine, a noncompetitive glutamatergic N-methyl-d-aspartate (NMDA) receptor antagon...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract Scopolamine is a nonselective muscarinic antagonist that has shown relatively rapid antidepressant effects, although to date the results are from limited clinical studies. Scopolamine reportedly has downstream signaling effects thought to be linked to neuroplasticity within glutamatergic synapses and consequent antidepressant action. In psychiatry, clinically validated pathways are unusual and thus merit further research in an effort develop more effect medicines for patients with mood disorders. Thus, we are faced with a unique opportunity to build on the clinical observation associated with scopolamine ...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract Conventional antidepressants typically require weeks of daily dosing to achieve full antidepressant response in antidepressant responders. A newly evolving group of compounds can engender more rapid response times in depressed patients. These drugs include the newly approved antidepressant (S)-ketamine (esketamine, Spravato). A seminal study by Furey and Drevets in 2006 showed antidepressant response in patients after only a few doses with the antimuscarinic drug scopolamine. Several clinical reports have generally confirmed scopolamine as a rapid-acting antidepressant. The data with scopolamine are consi...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract A single sub-anesthetic intravascular dose of the use-dependent NMDAR antagonist, ketamine, improves mood in patients with treatment resistant depression within hours that can last for days, creating an entirely new treatment strategy for the most seriously ill patients. However, the psychomimetic effects and abuse potential of ketamine require that new therapies be developed that maintain the rapid antidepressant effects of ketamine without the unwanted side effects. This necessitates a detailed understanding of what cellular and synaptic mechanisms are immediately activated once ketamine reaches the bra...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract Given that ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist that exerts rapid antidepressant effects in patients with treatment-resistant depression, also has undesirable adverse effects, agents that can be used as alternatives to ketamine have been actively pursued. Group II metabotropic glutamate (mGlu) receptors, consisting of mGlu2 and mGlu3 receptors, have emerged as one of the most promising targets in the development of ketamine-like antidepressants. Indeed, mGlu2/3 receptor antagonists have been demonstrated to exert rapid antidepressant effects in animal models and to be effica...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract A serious lack of effective pharmacotherapeutic interventions for posttraumatic stress disorder (PTSD) raises the urgent need for the development of novel treatments. Ketamine-a noncompetitive glutamate N-methyl-d-aspartate (NMDA) receptor antagonist in use for decades as an anesthetic and analgesic agent-has more recently been demonstrated to have rapid-onset antidepressant effects in patients with treatment-resistant depression (TRD). In the present review of ketamine as an emerging novel pharmacotherapeutic intervention for chronic PTSD, we discuss findings from the first proof-of-concept, randomized c...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract Major depressive disorder (MDD) is the leading cause of disability worldwide and reduces life expectancy. Achieving and sustaining remission from depression is challenging after initial improvement of an acute episode with an antidepressant, especially for patients whose depressive episodes have proven treatment-resistant in response to conventional antidepressant pharmacotherapy. While standard antidepressants are at least partly effective for the short-term treatment of acute depressive episodes of MDD, many patients relapse within 6 months of apparent clinical remission, with faster and higher rates ob...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract As a field, psychiatry is undergoing an exciting paradigm shift toward early identification and intervention that will likely minimize both the burden associated with severe mental illnesses as well as their duration. In this context, the rapid-acting antidepressant ketamine has revolutionized our understanding of antidepressant response and greatly expanded the pharmacologic armamentarium for treatment-resistant depression. Efforts to characterize biomarkers of ketamine response support a growing emphasis on early identification, which would allow clinicians to identify biologically enriched subgroups wi...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
More News: Addiction | Alcoholism | Children | Depression | Hospitals | Jobs | Men | Music Therapy | Psychiatry | Schizophrenia | Seasonal Affective Disorder | Smokers | Suicide